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Abstract  15 
The most commonly prescribed painkiller worldwide, paracetamol (acetaminophen, APAP) is 16 
also the predominant cause of acute liver failure (ALF), and therefore paracetamol-induced 17 
liver toxicity remains an important clinical problem. The standard clinical treatment framework 18 
for paracetamol overdose currently allows for antidote therapy decisions to be made based 19 
on a nomogram treatment line. This treatment threshold is lowered for patients adjudged to 20 
be highly susceptible to liver injury due to risk factors such as anorexia nervosa or bulimia. 21 
Additionally, both the original and adjusted clinical frameworks are highly dependent on 22 
knowledge from the patient regarding time since ingestion and initial dose amount, both of 23 
which are often highly unpredictable. We have recently developed a pre-clinical framework for 24 
predicting time since ingestion, initial dose amount and subsequent probability of liver injury 25 
based on novel biomarker concentrations. Here, we use identifiability analysis as a tool to 26 
increase confidence in our model parameter estimates and extend the framework to make 27 
predictions for both healthy and high-risk populations. Through pharmacokinetic-28 
pharmacodynamic model refinement, we identify thresholds that determine whether necrosis 29 
or apoptosis is the dominant form of cell death, which can be essential for effective ALF 30 
interventions. Using a single blood test, rather than the multiple tests required in the current 31 
clinical frameworks, our model provides overdose identification information applicable for 32 
healthy and high-risk individuals as well as quantitative measures of estimated liver injury 33 
probability.  34 
Keywords 35 
APAP; DILI; biomarkers; in-silico; pharmacokinetics; identifiability.   36 
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1 Introduction  37 
Paracetamol (acetaminophen, APAP), the most commonly prescribed painkiller in the world 38 
[1], is also the leading cause of acute liver failure (ALF) [2] and therefore represents a 39 
concerning global health issue [3]. In England and Wales, APAP poisoning results in 40 
approximately 40,000 hospital admissions, 20 liver transplants and 200 deaths per year [4]. 41 
Between 2015-2016, there was an 11% increase in deaths involving APAP in the UK [5]. In 42 
the USA, ALF is responsible for approximately 56,000 emergency room visits, 2,600 43 
hospitalisations and 500 deaths per year [6]. Considering this, the clinical overdose 44 
intervention treatment framework is found to be surprisingly sub-optimal. Administration 45 
decisions regarding the overdose antidote, N-Acetylcysteine (NAC), are currently based upon 46 
the nomogram treatment line [7] which, though influenced by a measurement of alanine 47 
aminotransferase (ALT), is also heavily dependent on patients’ knowledge of initial dose 48 
amount and time elapsed since ingestion; information which is often unreliable. Given this 49 
uncertainty, decisions on whether or not to administer the NAC antidote can be imprecise. 50 
Furthermore, unnecessary NAC administration can cause a range of side effects such as 51 
nausea, vomiting and anaphylactoid reaction, thereby exacerbating the problem of ill-informed 52 
treatment [8]. Such inaccurate treatment decisions have led to an estimated cost of £8.3 53 
million per year in the UK since 2012 [9]. 54 
APAP is predominantly metabolised in the liver via glucuronidation and sulphation pathways, 55 
with a small fraction being oxidised into the toxic metabolite, NAPQI. Detoxification of NAPQI 56 
occurs via conjugation with hepatic stores of glutathione (GSH) [10]. Therefore, although initial 57 
dose and time since ingestion are known to be the most important indicators of overdose 58 
severity level, additional factors affecting an individual’s ability to synthesise or maintain 59 
sufficiently high levels of GSH should also be considered [11]. Such factors may include age, 60 
pre-existing liver disease, concurrent use of alcohol and/or other liver-metabolised 61 
medications, genetic predispositions and acuity/chronicity of APAP use [3]. Patients with 62 
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known high-risk factors are currently measured against an amended nomogram treatment line 63 
when deciding whether or not to administer NAC [12].  64 
Crucially, the availability of GSH is known to be heavily dependent on the nutritional level of a 65 
patient. Therefore, malnourished patients, or those suffering from eating disorders (particularly 66 
anorexia or bulimia nervosa) are deemed to be at a particularly high risk of developing liver 67 
injury following overdose of APAP [11]. Eating disorder admissions have risen by 68 
approximately 34% since 2006 in the UK and, with anorexia having the highest mortality rate 69 
of all psychiatric disorders (often linked to suicide) [13], it is essential that quick and accurate 70 
treatment decisions for these high-risk patients can be made so that fatalities can be avoided. 71 
In addition to an increase in those patients with eating disorders, the prescription of 72 
medications combining APAP with opioids is likely to increase the incidence of unintentional 73 
APAP overdose, particularly in the USA where there is currently an opioid addiction epidemic 74 
[14]. Furthermore, the number of alcohol-related hospital admissions in England rose by 22% 75 
in the 10-year period leading up to 2016 [15]. Since patients with opioid and alcohol-related 76 
issues are known to have a higher susceptibility to APAP toxicity, there is an increasingly 77 
urgent need to improve intervention efficacy for the growing number of patients in these high-78 
risk groups. 79 
Some of the most important goals of medicine are to reduce pain and prolong life [16] and 80 
scientific research has allowed for significant advancements in achieving these goals. 81 
However, there is also an increasing impetus to reduce the extent of animal testing required 82 
to conduct medical research [17]. Quantitative systems toxicology (QST) modelling comprises 83 
a useful tool to reduce and refine animal testing and is now considered as both an essential 84 
component of modern toxicity testing and a foundation for individualised therapeutic treatment 85 
[18]. However, the utility of a QST model, as an abstract representation of the true biology, is 86 
limited by its simplifying assumptions and consequently there are often multiple aspects of the 87 
model that contain uncertainty. Not all states of a dynamic model can be directly measured 88 
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experimentally, and conversely, not all experimental data may be useful for model calibration, 89 
since the data itself may contain errors not accounted for by the model. These limitations can 90 
raise scepticism around QST model predictions and while it would be unrealistic to attempt to 91 
completely eradicate every level of error, it is crucial that any parameter uncertainties should 92 
be assessed, reported and minimised in order for these models to be truly useful in their 93 
predictions [19]. There are many existing and developing techniques to quantify uncertainty, 94 
and the chosen method often depends on the aims of the model. Identifiability analysis can 95 
be employed to determine whether model parameters can be uniquely identified based upon 96 
the structure of the model and data used, and sensitivity analyses can provide quantification 97 
of the dependency of model outputs to perturbations in the model parameters. 98 
We have recently developed a framework that uses a single sample, rather than multiple 99 
sample, approach to biomarker quantification in order to predict the probability of liver injury 100 
[20]. This model was optimised against fed mouse data and therefore is limited to applications 101 
relating to individuals with unimpaired clearance capacity. Through the application of 102 
uncertainty quantification techniques, we here identify areas within the original model structure 103 
that require improvement and use this knowledge to make the structure more relevant to the 104 
APAP toxicity clinical environment. There are many other in-silico models which focus on 105 
describing and understanding APAP-induced toxicity. Howell et al. [21] combined a large-106 
scale, mechanistic mathematical model (DILIsym®) with in-vitro data to compare DILI 107 
responses across species. Whilst their model has potential utility for in-vitro to in-vivo 108 
extrapolation, parameter identifiability was not assessed within their study. Reith et al. [22] 109 
clarified the role of glucuronidation and sulphation pathways in the hepatic metabolism of 110 
APAP. Ochoa et al. [23] reported a physiologically-based pharmacokinetic (PBPK) modelling 111 
approach to predict APAP and toxic metabolite concentrations, which were then used to 112 
estimate spatiotemporal cell integrity and the elimination rates of various substances. 113 
Zurlinden et al. [24] used a Bayesian inference approach within a PBPK model to estimate 114 
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initial APAP dose and quantify its uncertainty based on conventional biomarkers. Our model 115 
aims to optimise patient stratification and overdose treatment by incorporating a panel of novel 116 
mechanism-based biomarkers of increased sensitivity [25]. Remien et al. [26] also used 117 
conventional biomarkers to predict initial dose and time since overdose. Our work in [20] 118 
extended this previous work with the inclusion of novel biomarkers HMGB1 and K18. However, 119 
there is currently only one in-silico APAP model which takes into consideration individuals that 120 
may have depleted GSH stores. Navid et al. (2013) developed a multi-compartmental PBPK 121 
model of APAP metabolism in order to understand how nutritional deficiencies and certain 122 
lifestyle choices, such as alcohol consumption, affect GSH regeneration [27].  123 
PBPK models are increasingly being utilised to account for blood flow between organs, tissue 124 
partitioning, and predicting localised drug concentrations at the site of action [24, 28]. 125 
However, these large-scale models, while more physiologically relevant, favour complexity at 126 
the expense of mathematical tractability and subsequently contain an increased number of 127 
parameters that require estimation. The large scale of the models and amount of parameters 128 
to be optimised, often outweighing the amount and quality of data available for such a task, 129 
renders identifiability of model parameters problematic. Since the distribution and metabolism 130 
of APAP is well known, we opt for a smaller scale model which focuses on liver toxicity 131 
biomarkers. The smaller scale model allows for closer scrutiny of the model itself via 132 
techniques such as sensitivity analysis and identifiability analysis, providing mechanistic 133 
insight into structure, parameterisation and interactions within the system.  134 
In this study, we extend our original APAP overdose framework [20] to quantify the effects of 135 
various factors that impact upon GSH availability to develop an improved overdose 136 
identification framework. The mathematical model is refined using techniques from uncertainty 137 
analysis to account for mechanistic changes indicative of suppressed GSH capacity and 138 
optimised against additional data to improve its scope and predictive potential. Analysis of this 139 
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improved model provides predictions of initial dose, time since ingestion and probability of liver 140 
injury for both healthy and high-risk populations. 141 
2 Methods 142 
2.1 Experimental data description 143 
The mathematical model is parameterised against multiple experimental datasets. For the 144 
APAP PK element of the model, four datasets from two separate published studies [25, 26] 145 
recording APAP concentration over time in mice following intraperitoneal administration of  50, 146 
150, 500 and 530 mg/kg doses are used in both the original and extended framework. For the 147 
biomarker PD element of the model, in the original framework one experimental dataset is 148 
used [30] which records biomarkers (GSH, ALT, HMGB1, full and fragmented K18) over time 149 
following a 530 mg/kg APAP dose. In the extended framework, this dataset is also used, but 150 
with the addition of two other datasets from two separate studies [20, 27]. The first, [20], 151 
provides dose response data for mouse biomarker concentrations GSH, ALT, HMGB1 and 152 
fragmented K18 at 5 hours following APAP doses [0,150,300,530,750,1000] mg/kg. The 153 
second, [31], provides biomarker concentrations GSH, ALT, HMGB1, full and fragmented K18 154 
at 5 and 24 hours for both fed and fasted mice following a 530mg/kg APAP dose. All datasets 155 
described were used for optimisation of the model parameters. The data consists of a wide 156 
range of dosing scenarios to the extent that we do not extrapolate beyond these calibration 157 
ranges in subsequent model simulations. 158 
2.2 Parameter optimisation  159 
A multi-start technique is applied during parameter optimisation in an attempt to find the 160 
globally optimal parameter set following the restructuration of the original model [20]. All 161 
dynamic models are optimised by minimising the sum of squared errors (SSE) between model 162 
simulated output and the experimental data described in section 2.1 (fminsearch, Matlab [32]). 163 
The Matlab minimisation function uses a Nelder-Mead search algorithm to iteratively search 164 
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the parameter space until a local minimum is found [33]. Latin hypercube sampling was used 165 
to generate 1000 different initial estimates for each parameter (ranges defined in the 166 
supplementary material).  167 
2.3 Identifiability analysis 168 
Identifiability analysis is performed to visualise changes in SSE (deviation between model 169 
output and experimental data) following parameter perturbations and, subsequently, to 170 
determine the identifiability of each parameter in the model. We apply a method of identifiability 171 
analysis similar to the profile likelihood approach defined by the FRIAS research group [34]. 172 
Parameter estimates are either identifiable (unique minimum), practically unidentifiable 173 
(monotonic response), or structurally unidentifiable (negligible response) [35]. During this 174 
analysis, each individual parameter is tested separately for identifiability. This “test parameter” 175 
is varied by 20% intervals (from -50% to +200% of its original value). In each iteration, the 176 
modified test parameter is fixed, while all the other parameters in the model are varied in two 177 
ways: fixed at the optimum values (as found from previous multi-start optimisation); or 178 
randomly sampled from a Latin hypercube (bounds for sampling can be found in the 179 
supplementary material). For each test parameter iteration, the parameter set corresponding 180 
to the lowest SSE value is then identified. In this analysis, an identifiable parameter is defined 181 
as a parameter which, when perturbed from its initial (optimal) value (both positively and 182 
negatively), results in an increased SSE and therefore predicts a greater error between the 183 
model output and the data. If the SSE increases on only one side (i.e. in the positive or 184 
negative direction) of the test parameter, and remains relatively unchanged on the other side, 185 
this parameter is defined as practically unidentifiable; that is, either increasing or decreasing 186 
the test parameter value causes an increased error between the model output and the data. 187 
However, since the error between model output reduces as we head towards the test 188 
parameter, but then remains relatively unchanged for further perturbations in that direction, 189 
we cannot be confident that the parameter is uniquely optimal, since there are multiple values 190 
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that provide the same approximate SSE. However, since the optimum path does change in 191 
one direction, we have confidence that we are capturing some of the structure, and often these 192 
kind of ‘practical unidentifiabilities’ can be resolved by including more calibration data [34]. If 193 
the SSE value does not change either side of the original test parameter value, this parameter 194 
is known as structurally unidentifiable. This means that parameter optimisation via data-fitting 195 
is relatively insensitive to the choice of this parameter; the parameter cannot be uniquely 196 
determined and therefore even if removed entirely, values of other parameters could be 197 
suitably adjusted to compensate for the change in the model structure. During both sensitivity 198 
and identifiability analyses, model parameters are perturbed and subsequent changes in 199 
model output are studied. However, parameters are not re-optimised during sensitivity 200 
analysis. Identifiability analysis seeks to determine whether distinct model parameterisations 201 
could provide the same model solution. 202 
2.4 Model refinement 203 
2.4.1 APAP pharmacokinetic model 204 
Three datasets from three separate published studies [20, 26, 27] were used to parameterise 205 
the APAP pharmacokinetic (PK) model which is developed as an extension to our previous 206 
framework [20]. The PK model structure remains unchanged and is summarised below for 207 
completeness. Note that all the data used was obtained in studies of APAP dosing in mice 208 
(fed or fasted). Two ordinary differential equations (ODEs) are used to represent changes in 209 
APAP concentration within two PK compartments (central and peripheral) in the following 210 
system, 211 
 𝑑[𝐶$]
𝑑𝑡
=
𝑘)𝐷+𝑒-./0
𝑉$
+ 𝑘345𝐶67
𝑉6
𝑉$
− 𝑘43[𝐶$] − 𝑘9:[𝐶$], (1) 
 𝑑5𝐶67
𝑑𝑡
= 	𝑘43[𝐶$]
𝑉$
𝑉6
− 𝑘345𝐶67, (2) 
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where [𝐶$]	is the central compartment concentration (µmol/l) of APAP; [𝐶6]	is the peripheral 212 
compartment concentration (µmol/l) of APAP; and 𝑘) represents the absorption rate (h-1) from 213 
where APAP is administered (the peritoneal cavity in this case). The initial dose (µmol/kg) is 214 
given by 𝐷+; 𝑘34 represents the transfer rate (h-1) from peripheral to central compartment; 𝑘43 215 
represents the transfer rate (h-1) from central to peripheral compartment; 𝑉6 is the theoretical 216 
volume (l/kg) of the peripheral compartment; 𝑉$ is the theoretical volume (l/kg) of the central 217 
compartment; 𝑘9: represents the overall elimination rate (summation of excretion and 218 
metabolism processes) (h-1); and 𝑡 represents the time variable (h). Further details of the 219 
APAP pharmacokinetic model can be found in our previous publication [20]. 220 
2.4.2 Pharmacodynamic models 221 
Previously, the pharmacodynamic (PD) element of the model was parameterised using a 222 
dataset consisting of GSH and biomarker (ALT, HMGB1, full and fragmented K18) time-course 223 
concentrations following a 530 mg/kg intraperitoneal APAP dose [20]. In this paper, we extend 224 
this optimisation to also include dose-response data consisting of plasma biomarker 225 
concentrations at 5 hours following APAP doses ranging from 0-1000 mg/kg [20] and a dataset 226 
consisting of biomarker concentrations at 5 and 24 hours for both fed and fasted mice following 227 
a 530 mg/kg APAP dose [31]. This extension is necessary in order to account for differing 228 
mechanisms of cell death, i.e. apoptosis versus necrosis, and also to account for an increased 229 
dosing range more representative of the clinical environment. 230 
2.4.2.1 Glutathione dynamics 231 
In our model, paracetamol toxicity biomarker dynamics are assumed to be directly dependent 232 
on GSH depletion; i.e., during APAP overdose cases when GSH pools deplete, NAPQI 233 
accumulates potentially leading to liver toxicity and associated biomarker release. The GSH 234 
model component  remains identical to our previously defined model [20], namely: 235 
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𝑑[𝑔𝑠ℎ]
𝑑𝑡
= 𝑘@(𝑔𝑠ℎ+ − [𝑔𝑠ℎ]) −
𝜉𝑘9:𝐶$[𝑔𝑠ℎ]
[𝑔𝑠ℎ] + 𝑘6D
	, (3) 
where 𝑘@ is the basal removal rate (h-1) of GSH (including background usage); 𝑔𝑠ℎ+ is the 236 
baseline concentration (µmol/l) of GSH in the APAP-free steady state; 𝜉 is the proportion of 237 
eliminated APAP that is transformed into NAPQI; 𝑘9: is the APAP elimination rate; 𝑘6D is the 238 
ratio of NAPQI forming other protein adducts, relative to being detoxified by GSH, and 239 
[𝑔𝑠ℎ]	represents the concentration (µmol/l) of GSH. Further details on the derivation of the 240 
GSH model can be found in the supplementary material of our previous study [20]. For the 241 
fasted case, basal GSH dynamics are modified to simulate a delay in GSH repletion due to 242 
depleted co-factors stemming from the reduced food intake. These slower dynamics are 243 
incorporated by rescaling 𝑘@ by an additional parameter, 𝛿 < 1 (so that 𝑘@ becomes 𝛿𝑘@ < 𝑘@). 244 
2.4.2.2 ALT and HMGB1 dynamics 245 
The toxic response of biomarkers ALT and HMGB1 to APAP overdose is mathematically 246 
modelled as in the previous study [20], namely: 247 
𝑑[𝑟]
𝑑𝑡
= 𝑟+𝑘@H0 I
𝑅K+L + 𝑔𝑠ℎ+L
𝑅K+L
M I1 −
𝑔O)P[𝑔𝑠ℎ]L
𝑅K+L + [𝑔𝑠ℎ]L
M − 𝑘@H0[𝑟], (4) 
Where [𝑟] is the biomarker concentration (µmol/l), 𝑟+ is the respective biomarker baseline 248 
(µmol/l); 𝑘@H0 is the natural decay rate (h-1) of the biomarker; 𝑅K+ represents the concentration 249 
(µmol/l) of (GSH) at which the biomarker response to GSH is half its maximal rate; and 𝑛 is a 250 
Hill coefficient indicating the steepness of the biomarker response [36]. Parameter 𝑔O)P 251 
represents the maximal regulatory effect of GSH on biomarker production. In the fed case, we 252 
set 𝑔O)P = 1 such that GSH depletion is solely responsible for augmented biomarker 253 
production and therefore for the APAP-free steady state, the biomarker is only produced at 254 
low, basal levels maintaining the background steady state value, 𝑟+. This element of the model 255 
is therefore identical to the previous study. However, experimental observations show that 256 
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background biomarker levels are higher for fasted animals. We therefore take 𝑔O)P < 1	in the 257 
fasted case to account for these higher background values.  258 
2.4.2.3 K18 dynamics 259 
Keratin-18 (K18) is an intermediate filament protein expressed in abundant levels in 260 
hepatocytes that undergoes caspase-mediated cleavage during apoptosis, resulting in the 261 
release of fragmented K18 upon cell death. This feature makes K18 a useful biomarker to 262 
distinguish between apoptosis and necrosis as the presence of full (as opposed to fragmented) 263 
K18 instead suggests the occurrence of necrosis [37]. Full and fragmented K18 are therefore 264 
modelled as necrotic and apoptotic forms of the same single biomarker, K18. However, we 265 
could not find sufficient data for K18 to properly parameterise a model of the form (4) for both 266 
full and fragmented K18. We therefore adopt a simple form of K18 using piecewise linear 267 
representations of (4), as illustrated in Figure 1. That is, the dynamics of the necrotic marker, 268 
full K18, are modelled in the following way,   269 
𝑑[𝑘18]
𝑑𝑡
= 𝑟+4S𝑘@H04S + 𝑘OTP𝑘UL4S𝐻W𝑔𝑠ℎXY − [𝑔𝑠ℎ]Z − 𝑘@H0
4S [𝑘18], (5) 
where 𝑟+4S is the baseline concentration (µmol/l) of full K18; 𝑘@H04S  is the natural decay rate of 270 
the biomarker; 𝑘UL4S is the production rate of the biomarker; 𝑔𝑠ℎXY is the GSH threshold below 271 
which additional K18 production is induced due to cell death; [𝑘18]	represents the 272 
concentration of full K18 (µmol/l); and 𝑘O)P is a measure of the production capability of full 273 
K18 (i.e., 0<𝑘O)P<1; since there is a finite quantity of cells, there is a maximum amount of 274 
biomarker that can be produced). In the fed case, we take 𝑘O)P = 1. Since fasting in mice 275 
causes extensive cell loss at early time points [31], the amount of biomarker able to be 276 
produced from a smaller amount of cells will therefore be smaller. To account for this, in the 277 
fasted case, we take  𝑘O)P < 1.𝐻(𝑥) is the Heaviside function where 𝐻(𝑥) = 1 when 𝑥 > 0 278 
and 𝐻(𝑥) = 0 when 𝑥 < 0. 279 
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 280 
Figure 1: Relationship between full and fragmented K18 biomarker production and GSH 281 
concentration. Black lines represent the full K18 relationship, and red lines represent the 282 
fragmented K18 relationship (solid lines represent the fed case and dashed lines represent 283 
the fasted case). As GSH depletes from baseline, 𝑔𝑠ℎ+, and reaches a certain threshold, 284 
𝑔𝑠ℎXY, production of full and fragmented K18 begins. Full K18 production continues for any 285 
GSH concentration below this threshold; however, fragmented K18 production ceases beyond 286 
a GSH concentration of 𝑔𝑠ℎX_ in the fed case and 𝑔𝑠ℎX_ + 𝜀 in the fasted case. 287 
Similarly, the dynamics of fragmented K18 are modelled in the following way,  288 
𝑑[𝑓𝑘18]
𝑑𝑡
= 𝑟+
b4S𝑘@H0
b4S + 𝑘UL
b4S c𝐻W[𝑔𝑠ℎ] − 𝑔𝑠ℎX_ − 𝜀Z − 𝐻W[𝑔𝑠ℎ] − g𝑠ℎXYZe − 𝑘@H0
b4S[𝑓𝑘18], (6) 
where	𝑟+
b4S is the baseline concentration (µmol/l) of fragmented K18; 𝑘@H0
b4S is the natural decay 289 
rate (h-1) of the biomarker; 𝑘UL
b4S is the production rate (h-1) of the biomarker; 𝑔𝑠ℎXY is the GSH 290 
threshold below which augmented production of fragmented K18 production is initiated, 291 
and	𝑔𝑠ℎX_ is the GSH threshold below which augmented production ceases due to a switch 292 
from apoptosis to necrosis. [𝑓𝑘18]	is the concentration (µmol/l) of fragmented K18. For the fed 293 
case, production begins at 𝑔𝑠ℎXY	and ceases at 𝑔𝑠ℎX_.	For the fasted case however, necrosis 294 
will be more apparent than apoptosis, and less GSH depletion will be required before 295 
apoptosis is no longer sustainable. To account for this, 𝜀 represents the change in GSH 296 
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threshold denoting the switch to necrosis, i.e., 𝜀 = 0 in the fed case and 𝜀 > 0 in the fasted 297 
case.  298 
 All initial conditions and parameter values for the PKPD model can be found in the 299 
supplementary material. 300 
2.5 Statistical analysis 301 
2.5.1 Virtual population simulation  302 
Model predictions are made for three virtually simulated populations: healthy, high-risk, and a 303 
mixture of healthy and high-risk individuals. Healthy populations are based on biomarker 304 
concentrations simulated with parameter values derived from fed data. High-risk populations 305 
are based on biomarker concentrations simulated with parameter values derived from fasted 306 
data. The mixed population is based on a weighting of the biomarker concentrations simulated 307 
with parameter values derived from fed/fasted data, with respect to the proportion of 308 
healthy/high risk patients that are seen in the clinic. Craig et al. [38] analysed overdose 309 
patterns in 663 patients over 16 years and found that 42.3% patients had psychiatric history, 310 
45.3% had alcohol abuse, and 44.7% combined the overdose with alcohol. In line with this, 311 
44.1% of the population is assumed to be high-risk and 55.9% are assumed to be healthy in 312 
our mixed population case.  313 
Each virtual population dataset consists of 1000 independent and individually distributed in-314 
silico individuals, given a random dose selected from a uniform distribution of range 0-1000 315 
mg/kg. Biomarker concentrations are subsequently extracted at a random time-point from a 316 
uniform range between 0-24 hours. Simulated concentrations are normalised in the range [0,1] 317 
using the min-max normalisation method [39] to account for varying orders of magnitude. 318 
Experimental noise is replicated in the in-silico data by applying observed in-vivo standard 319 
deviations in biomarker concentrations from an APAP study performed by Antoine et al. (2009) 320 
(ALT s.d = 11.22, HMGB1 s.d = 0.00097, K18 s.d = 2.39, fragmented K18 s.d = 0.12 µmol/l). 321 
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2.5.2 Predicting time since administration and initial dose 322 
2.5.2.1 Multiple linear regression 323 
Normality tests indicate that the simulated data is non-normally distributed [40]. Improvements 324 
to the linear model, made by employing interaction/polynomic terms, are insignificant, and 325 
hence a robust multiple linear regression model [41]  is applied to the in-silico-derived data in 326 
order to predict time since administration and initial dose. 327 
2.5.2.2 Visualisation 328 
For each in-silico individual, the t-Distributed Stochastic Neighbour Embedding (T-SNE) 329 
method [42] is applied to visualise the dataset constituted by the aforementioned variables 330 
(APAP, GSH, ALT, HMGB1, K18, fragmented K18). Two-dimensional scatter plots of the 331 
embedded data are employed in order to examine class structure and separability whilst 332 
retaining model variation.  333 
2.5.2.3 Classification 334 
In order to test the predictive potential of biomarker concentrations, critical ranges for 335 
predicting time since administration are defined as (0-2], (2-5], (5-10], (10-15] and (15-24] 336 
hours. For dose, the ranges are [0-200], [201-400] and [401-1000] mg/kg, capturing 337 
therapeutic, small, and large (overdoses), respectively. A number of classification techniques 338 
are applied and compared, further details of which can be found in the supplementary 339 
information of our previous study [20].  340 
2.5.3 Predicting probability of liver injury 341 
Our previously defined binary logistic regression framework [20] uses experimental biomarker 342 
time-course data [30] to predict a corresponding histology score for each mouse. The whole 343 
panel of biomarkers was tested, and analysis found HMGB1 concentration to be the most 344 
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significant in predicting the probability of liver injury. The resultant  logistic regression model 345 
is used here in combination with PK-PD model simulations to predict the drug-induced liver 346 
injury (DILI) probability [43].  347 
3 Results  348 
3.1 Identifiability analysis – original model structure 349 
Parameters in the original model structure are individually perturbed to visualise resultant 350 
differences between model output and experimental data. These changes are assessed to 351 
determine the identifiability of each parameter and identify where changes may be necessary. 352 
As seen in Figure 2, 10 out of 21 parameters are identifiable. The ALT component of the model 353 
is identifiable, and all but one of the parameters in the PK component are identifiable. 354 
However, the HMGB1 component of the model is structurally unidentifiable, and practical 355 
unidentifiabilities exist in all other elements of the model. Five parameters are identified as 356 
practically unidentifiable. There are 3 within the GSH component: the ratio of NAPQI forming 357 
other protein adducts relative to being detoxified by GSH (𝑘6D); the proportion of eliminated 358 
APAP that is transformed into NAPQI (𝜉); the basal removal rate of GSH (𝑘@). The remaining 359 
practical unidentifiabilities are found within the K18 and fragmented K18 components of the 360 
model: the decay rate of full K18 (𝐾18.@H0); and the fragmented K18 hill coefficient (𝑓18L). 361 
The remaining 6 parameters are structurally unidentifiable. These include the theoretical 362 
volume of the peripheral compartment (𝑉6) from the PK component and all parameters from 363 
the HMGB1 component:  the hill coefficient (𝐻L); the GSH concentration at which the 364 
augmented production rate of HMGB1 reaches 50% of its maximum (𝐻ghK+); and the decay 365 
rate (𝐻.@H0). Two out of three parameters within the fragmented K18 component are 366 
structurally unidentifiable: the GSH concentration at which the augmented production rate of 367 
fragmented K18 reaches 50% of its maximum (𝑓18ghK+); and the decay rate (𝑓18.@H0). 368 
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 369 
Figure 2: Identifiability analysis of the original model structure [20]. Each test parameter, 370 
was fixed at 20% intervals, and the other parameters in the model allowed to vary. The 371 
percentage change of resultant optimised function values (SSE) are plotted at each interval 372 
(on log-scale). The lowest SSE change is represented by a white box; darker colours show an 373 
increase in SSE change. The highest SSE change is represented by a black box. Blue dashed 374 
bounds indicate where the parameter is identifiable at the 0.5% level. Red bounds indicate 375 
where the parameter is identifiable at the 1% level. A parameter is identifiable at the 1% level 376 
if it is bounded by red in both the positive and negative parameter-change directions. If the 377 
parameter is bounded by red in one direction and blue in the other direction, it is identifiable 378 
at the 0.5% level but practically unidentifiable at the 1% level. A parameter is practically 379 
unidentifiable if it is bounded by red/blue in either the positive or negative parameter change 380 
direction, and unbounded in the opposite direction. A parameter is structurally unidentifiable if 381 
it is unbounded in both positive and negative parameter-change directions (no red/black 382 
bounds exist for the whole range of parameter changes). For example, 𝐴ghK+ is identifiable at 383 
the 1% level, 𝐾18ghK+ is identifiable at the 0.5% level but practically unidentifiable at the 1% 384 
level, 𝑓18L is practically unidentifiable, 𝑉6 is structurally unidentifiable. 385 
3.2 Re-parameterisation 386 
Following model restructuration and re-parameterisation against the multiple datasets 387 
(increased dose range and fasted data), we identify a number of parameter adjustments. In 388 
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cases where parameters are common to both model structures, percentage changes in their 389 
values following re-parameterisation are shown in Table 1. The baseline level of GSH, 𝐺𝑆𝐻+, 390 
is now optimised against the data rather than fixed as in the previous model. The resultant 391 
value reduces by almost 20% to 559.47 µmol/l. The proportion of CYP-activated APAP that is 392 
transformed into NAPQI, 𝜉, increases to around 80%, but there is also an increased level of 393 
NAPQI detoxification resulting from the re-parameterisation (represented by a 22.1% 394 
decrease in parameter 𝑘6D, the ratio of NAPQI forming other protein adducts relative to 395 
detoxification). The new parameter, 𝛿, incorporates an effective delay in GSH repletion in the 396 
fasted case due to depleted co-factors. The optimised value is 0.0483 and considerably 397 
reduces the timescale of GSH dynamics in the fasted case. 398 
19 
 
 
  Optimised value  
Model Parameter Original Re-parameterised % change  
APAP 𝑘T (h-1) 9.05 8.6152 -4.8% 
𝑘9: (h-1) 0.52 0.5459 +5% 
𝑘43 (h-1) 0.42 0.4502 +7.2% 
𝑉$ (l/kg) 0.02 0.0220 +10% 
𝑉l (l/kg) 0.01 0.2102 +2000% 
𝑘34 (h-1) 1.01 1.0315 +2.1% 
GSH 𝑔𝑠ℎ+ (µmol/l) 696.9136  559.47497 -19.7% 
𝑘6D  71.06 55.33401 -22.1% 
𝜉  0.68 0.80571 +18.5% 
𝑘@ (h-1) 0.25 0.78807 +215% 
ALT 𝑅+ (µmol/l) 0.7626 0.7626 0% 
𝑛  9.26 4.3324 -53.2% 
𝑅K+ (µmol/l) 227.67 35.6531 -84.3% 
𝑘@H0 (h-1) 0.0002 0.0004 +1% 
HMGB1 𝑅+ (µmol/l) 0.0005 0.0005 0% 
𝑛  4.90 2.3445 -51.2% 
𝑅K+ (µmol/l) 399.08 75.2828 -81.1% 
𝑘@H0 (h-1) 0.35 0.0964 -72.5% 
Full K18 𝑟+4S(µmol/l) 0.0146 0.0088 -39.73% 
𝑘@H04S  (h-1) 0.0007 0.0031 +342.9% 
Fragmented-K18 𝑟+
b4S(µmol/l) 0.0642 0.0977 +52.2% 
𝑘@H0
b4S(h-1)  0.02 0.0031 -84.5% 
Table 1: Parameter changes following model refinement. Any parameter that remained 399 
within the new model structure is defined, with its original value and the re-parameterised 400 
value. Percentage changes are also defined. 401 
Following re-parameterisation, we found that an increased amount of GSH depletion is 402 
required for the GSH-induced ALT response to be half of its maximal value, i.e., 67% GSH 403 
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depletion was required before whereas almost 94% is required now. Although more GSH 404 
depletion is also required for HMGB1 induction, this biomarker response is still faster than that 405 
of ALT, since it has reached 50% maximal response rate at around 86.5% GSH depletion. For 406 
Full-K18, results from the optimisation suggest that augmented production of the biomarker 407 
will occur when GSH decreases below 174.5205 µmol/l (~68.8% depletion). Fragmented K18 408 
is also induced at this level of GSH; however, if GSH is further depleted to 167.3663 µmol/l, 409 
augmented production of this apoptosis marker would cease, and the necrotic, full version of 410 
the biomarker would then dominate. In the fasted case, this threshold increases by 5.0457 411 
µmol/l (𝜀) such that the necrotic switch (as indicated by the absence of K18 fragmentation) 412 
occurs when GSH is depleted beyond 172.412 µmol/l. Optimised model simulations are 413 
plotted and compared with the time-course data (Figure 3) and the dose-response data (Figure 414 
4). Dose-response data was unavailable for full K18 at the time of investigation. Therefore, 415 
the K18 parameters within the model structure are predominantly optimised against high-dose 416 
data which may explain the slight under-prediction shown in the fragmented K18 simulations. 417 
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Figure 3: Model simulations versus time-course data. (A): APAP concentration simulations 418 
are plotted for 50 (green), 150 (blue), 500 (pink) and 530 (black) mg/kg doses of APAP. (B): 419 
Fed and fasted simulations (green and red respectively) are plotted for GSH and biomarkers 420 
(ALT, HMGB1, Full and fragmented K18) following a 530 mg/kg dose of APAP.  421 
 422 
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 423 
Figure 4: Model simulations versus dose-response data. Dashed lines represent dose-424 
response simulations of GSH and biomarkers (ALT, HMGB1 and fragmented K18) in fed mice 425 
for a range of APAP doses (0,150,300,530,750,1000 mg/kg). Solid lines represent the 426 
experimental data each model was calibrated against. 427 
 428 
3.3 Identifiability analysis – re-parameterised model 429 
Parameters in the refined model are individually perturbed to visualise resultant differences 430 
between model output and experimental data. These changes are assessed to determine the 431 
identifiability of each parameter. 16 out of 27 parameters are now identifiable. Parameter 432 
identifiability has remained for the ALT component, and the GSH component of the model is 433 
now also completely identifiable. The PK component remains identifiable, other than the 434 
volume of the peripheral compartment (𝑉6), which remains structurally unidentifiable. There 435 
are some unidentifiabilities still present within this updated model. Other structurally 436 
unidentifiable parameters include: 𝐻ghK+, 𝐻.@H0	and 𝐻mO)P from the HMGB1 component; and  437 
𝐾18.@H0, 𝑓.UL, 𝑓.@H0,	𝑔𝑠ℎX_ and 𝜀 from the full and fragmented K18 component. Practical 438 
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unidentifiabilities remain for two parameters: the HMGB1 hill coefficient (𝐻L) and the 439 
production capability of full K18 (𝑘O)P). 440 
 441 
Figure 5: Identifiability analysis of the re-parameterised model structure. Figure 442 
annotation is the same as for Figure 2. Example results from figure: 𝐴ghK+ is identifiable at the 443 
1% level, 𝐻L is practically unidentifiable, 𝑉6 is structurally unidentifiable. 444 
Less than half of the parameters (47%) are identifiable in the original model structure (Figure 445 
6). Only the ALT component of the model is completely identifiable. 24% of the model 446 
parameters are practically unidentifiable and 29% are structurally unidentifiable. However, 447 
following model refinement, the identifiability results have improved; the percentage of 448 
identifiable parameters has increased to above half of the parameters (60%). Parameter 449 
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identifiability has been maintained for the ALT component of the model and the percentage of 450 
practical unidentifiabilities has reduced from 24% to 7%. The percentage of structural 451 
unidentifiabilities is approximately the same (29% compared to 33%). Whilst the GSH 452 
component is unidentifiable in the original model, it is now completely identifiable in the refined 453 
model. Although unidentifiabilities have improved for parameters in the HMGB1, K18 and f-454 
K18 components, there are still some that remain. 455 
 456 
Figure 6: Parameter identifiability comparison between the original and refined model. 457 
Each column represents a different sub-component of the APAP PKPD model. Each element 458 
(or square) represents the parameter’s identifiability within the model. Triangles in the bottom 459 
left-hand corner of each element represent the parameter’s identifiability in the original model 460 
structure. Triangles in the top right-hand corner of each element represent the parameter’s 461 
identifiability in the refined model structure. If the triangle is red, the parameter is structurally 462 
unidentifiable; if the triangle is yellow, the parameter is practically unidentifiable; if the triangle 463 
is green, the parameter is identifiable. If the triangle is grey, the parameter was not present 464 
within the corresponding model structure, and therefore could not be tested for identifiability. 465 
 466 
 467 
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3.4 Predicting an exact time since administration of initial APAP dose 468 
Simulations of the refined model create in-silico derived populations. Robust multiple linear 469 
regression is applied to biomarker concentrations from each population in order to predict an 470 
exact time since ingestion and initial APAP dose. For the healthy population, an exact time 471 
since administration can be estimated with an error of approximately 3.9 hours, and an exact 472 
initial dose amount can be estimated with an error of approximately 66.14 mg/kg (Table 2). 473 
  
Healthy Population 
 
 
High-risk Population 
 
Mixed Population 
Predictors 
 
Time 
 
Dose Time 
 
Dose Time 
 
Dose 
APAP Conc. -16.549*** 
(1.1785) 
 
673.985*** 
(17.0745) 
-9.5093*** 
(0.5963) 
 
1295.366*** 
(47.8525) 
-18.122*** 
(0.9542) 
 
909.341*** 
(17.8005) 
ALT conc. 8.972*** 
(0.9533) 
 
 
515.625*** 
(13.8110) 
5.5034*** 
(0.6537) 
 
695.2118*** 
(52.4551) 
1.4573 
(0.9228) 
 
 
655.0837*** 
(17.2145) 
HMGB1 conc. -22.035*** 
(0.9113) 
 
-23.3880 
(13.2028) 
-8.8119*** 
(0.5440) 
 
367.0774*** 
(43.6578) 
-17.869*** 
(0.7705) 
 
289.2333*** 
(14.3736) 
FullK18 conc. 7.521*** 
(1.0632) 
 
479.137*** 
(15.4035) 
21.0427*** 
(0.4743) 
 
-154.2403*** 
(38.0652) 
22.3833*** 
(0.9145) 
 
229.0486*** 
(17.0605) 
Fragmented 
K18 conc. 
-4.599* 
(1.3895) 
151.975*** 
(20.1309) 
 
3.8472*** 
(0.5962) 
86.7133 
(47.8445) 
-0.1079 
(0.8321) 
33.8383* 
(15.5231) 
 
 
Constant 14.918*** 
(0.3074) 
 
77.247*** 
(4.4529) 
5.8083*** 
(0.2527) 
-80.145*** 
(20.2759) 
12.6308*** 
(0.3694) 
 
-65.6354*** 
(6.8914) 
Residual Std. 
Error  
(df == 994) 
 
3.907 
 
66.14 
 
2.118 
 
184.1 
 
3.485 
 
73.73 
 
Note: 
*p<0.05; 
**p<0.01; 
***p<0 
      
Table 2: Robust multiple linear regression analysis results. Independent variable 474 
coefficients for predicting time and dose respectively for healthy, high-risk and mixed 475 
populations. The first number in each element of the table represents the biomarker coefficient 476 
in the regression model and the second number represents the corresponding error. For 477 
example, -16.549 is the APAP concentration coefficient in the healthy population model 478 
predicting time since administration, and this coefficient has an error of 1.1785. The standard 479 
error of overall model predictions is provided. The significance of each biomarker in the model 480 
is indicated by the number of asterisks (see note). 481 
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Time since administration can be predicted more accurately in the high-risk population, with a 482 
standard error of 2.118 hours. It is much harder to predict the initial dose in the high-risk 483 
population, however, with the standard error being almost triple that of the model for the 484 
healthy population (184.1 mg/kg). Predictions for an assumed mixed population are similar to 485 
that of the healthy population, with a slight improvement in predicting time since administration 486 
(standard error 3.485 hours) and a slight reduction in accuracy for predicting initial dose 487 
(standard error 73.73 mg/kg). All biomarkers are significant in predicting time since 488 
administration in a healthy population and high-risk population independently. However, when 489 
assuming a mixed population, ALT and fragmented K18 are no longer significant. When 490 
predicting dose in a mixed population, all biomarkers are significant; however, HMGB1 is not 491 
significant in the healthy population, and fragmented K18 is not significant in the high-risk 492 
population. 493 
3.5 Identifying time/dose category following APAP dose 494 
T-SNE visualisation is applied to the in-silico derived data to investigate time/dose class 495 
structure and separability and subsequently various classification techniques are also 496 
employed, using the biomarker concentrations of the in-silico observations in an attempt to 497 
classify a time/dose category. Differences in levels of discrimination regarding initial dose and 498 
time since administration for healthy, high-risk and mixed populations can be seen for each 499 
case by embedding the in-silico derived data in 2-dimensions using T-SNE (Figure 7). Both 500 
variables, time since administration and initial dose, can be reasonably separated in all 501 
healthy, high-risk and mixed populations. This result is supported by the reasonable accuracy 502 
rates of the classification techniques. Visualising the healthy population (Figure 7A), shows 503 
that there is a cluster of observations on the right-hand-side where the time since 504 
administration is difficult to discriminate from the biomarker concentrations. Visualising this 505 
same cluster of observations with regards to the initial dose, however, shows that these 506 
correspond to low-dose situations (Figure 7B). From measuring biomarker concentrations, a 507 
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correct time since administration category could be predicted with 69.9% accuracy for the 508 
healthy population, and a correct dose category can be predicted with 91.5% accuracy. These 509 
results are indicated in Table 3. A time since administration category is easier to predict in the 510 
high-risk category (80.4% accuracy). However, predictions for initial dose are less accurate 511 
than the healthy population (79%). If an observation is assumed to be taken from a mixed 512 
population, the prediction accuracy is similar to that of a healthy population, with results of 513 
69.94% and 89.5% for time since administration and initial dose respectively. In our previous 514 
study, a correct time category could be predicted with 72.8% accuracy and a correct dose 515 
category could be predicted with 86.5% accuracy [20]. For a healthy population, the time 516 
classification results have slightly worsened. However, the dose classification results have 517 
slightly improved. 518 
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Figure 7. Visualisation and classification of time-since-administration and dose results 520 
for healthy, high-risk and mixed populations. For time-since-administration, dark green 521 
represents class [0-2), orange represents [2-5), blue represents [5-10), pink represents [10-522 
15) and pale green represents [15-24) hours. For dose, green represents [0-200], orange 523 
represents [201-400] and blue represents [401-1000] mg/kg. TSNE visualisations of in-silico 524 
mouse observations with respect to time since administration and dose can be seen in (A)-(B) 525 
for the healthy population, (C)-(D) for the high-risk population and (E)-(F) for the average 526 
population. 527 
 528 
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Healthy Population 
 
 
High-risk Population 
 
Mixed Population 
Classification  
Method 
 
Time 
 
Dose Time 
 
Dose Time 
 
Dose 
KNN 
Regression 
66.2% 91.5% 80.4% 79% 69.5% 87.4% 
Naïve Bayes 
 
64.4% 91.3% 76.2%        72.7%      68.2% 88.5% 
Multinomial 
logistic 
regression 
 
68% 90.8% 73.1% 77.1% 75.7% 89.5% 
Ordinal logistic 
regression 
 
53.7% 90% 67.8% 78.1% 57.2% 87.5% 
Linear 
discriminant 
Analysis 
 
59.3% 90.7% 72.5% 77.9% 65.8% 87.8% 
Quadratic 
discriminant 
analysis 
69.9% 90.4% 76.8% 71.7% 69.94% 86.8% 
Table 3: Classification accuracy of predictions based on biomarker concentrations for 529 
healthy, high-risk and mixed populations. For example, the Quadratic discriminant analysis 530 
model can predict the correct time since administration category in the healthy population with 531 
69.9% accuracy.  532 
 533 
Figure 8 shows how the probability of liver injury changes over time for both healthy and high-534 
risk populations, for doses between 0-1000 mg/kg. The model-derived probabilities are 535 
dependent only on HMGB1 concentration (as predicted by our previous logistic regression 536 
model [20]). A threshold probability of 0.5 is used to determine the likelihood of DILI. Any 537 
observation within the white contour boundary is therefore predicted to be representative of 538 
probable liver injury.  539 
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 540 
Figure 8. Proposed framework for predicting probability of liver injury dependent upon 541 
dose, time and HMGB1 concentration. The plotted frameworks are representative of both 542 
healthy (A) and high-risk (B) populations. In each, the white contour indicates the threshold of 543 
0.5 probability of liver injury; the red dashed-line represents the currently used APAP dose for 544 
toxicity studies in mice; the white dashed-line represents toxic dose as proposed by our model; 545 
and the green dashed-line indicates currently considered therapeutic dose for mice. In the 546 
high-risk population, the toxic dose proposed by our model and the therapeutic dose are 547 
identical. 548 
For the healthy population, the time-frame for biomarker concentrations representing those of 549 
probable liver injury is around 2-18 hours. The dose threshold at which toxicity is predicted to 550 
be likely to occur is approximately 350 mg/kg. Note that this prediction is only slightly above 551 
the currently used toxic dose (300 mg/kg) [44]. The framework for a healthy population 552 
suggests that there is almost 100% chance of liver injury when the dose is only slightly higher 553 
than this amount. 554 
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For the fasted population, however, at the currently recommended therapeutic APAP dose (60 555 
mg/kg), there is approximately 50% chance of liver injury progression. For any dose above 556 
the known therapeutic threshold, liver injury progression is predicted to be highly probable 557 
(above 60%); beyond approximately 2.5 h post-dose, HMGB1 concentrations remain 558 
indicative of highly probable liver injury for the whole time-course. These results are 559 
summarised in Table 4. 560 
Population Dose likely to induce liver 
injury 
Time frame liver injury 
likely to occur 
Healthy >350 mg/kg 2-18 h 
High-risk >60 mg/kg >2.5 h 
Table 4: Critical dose and time ranges indicative of potential liver injury in both healthy 561 
and high-risk populations. 562 
3.6 Visualising the probability of liver injury following an APAP dose 563 
For each observation within the in-silico population, simulated HMGB1 concentrations, based 564 
on our findings in [20], are used within the logistic regression model to determine the 565 
corresponding probability of liver injury. Each in-silico observation is then visualised and 566 
discriminated by their resultant liver injury probability using the TSNE method (Figure 9). 567 
Relatively safe/unsafe observations are identifiable in both healthy and high-risk populations. 568 
For the healthy population (Figure 9A) most of the observations have less than around 35% 569 
chance of DILI progression. The small group of observations representing at-risk individuals 570 
can be identified at the top, right-hand side of the image, portrayed by red markers. In stark 571 
contrast, most of the in-silico observations have almost 100% chance of liver injury 572 
progression in the high-risk population, as can be seen by the dominance of red markers in 573 
Figure 9B. The observations corresponding to lower injury potential are indicated in the central 574 
and the left-hand side of the plot. 575 
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 576 
Figure 9: 2-dimensional TSNE visualisation of in-silico observations with respect to 577 
estimated probability of liver injury. Separated liver injury probabilities are visualised for a 578 
range of in-silico generated inputs for both healthy (A) and high-risk (B) populations. DILI 579 
probabilities (0-1) for each individual observation are indicated by the colour bar. 580 
 581 
4 Discussion  582 
The current clinical APAP framework  is known to be inaccurate, mainly due to a dependency 583 
on known time of ingestion, but also due to inaccurate estimates of initial dose based on 584 
biomarkers currently criticised for being insensitive [25]. We previously reported a promising 585 
computational framework for predicting the probability of liver injury based on novel biomarker 586 
concentrations  [20]. However, the identifiability analysis performed within this study highlights 587 
parameter unidentifiabilities within the model that required addressing prior to any further 588 
clinical application. Results of the analysis show where the original model required structural 589 
changes and also where more data was required in order to increase confidence in 590 
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predictions. Therefore, we have re-structured the original model where necessary and re-591 
parameterised against additional data (from both fed and fasted mice). Identifiability analysis 592 
of the newly defined model structure found that only 7% of parameters are practically 593 
unidentifiable (compared with 24% previously).  594 
As well as improving confidence in the mathematical representation of the system, we have 595 
here provided a model that is more representative of the clinical environment by including a 596 
wider range of APAP doses. Furthermore, the new treatment framework can now be adjusted 597 
for individuals considered to be at high risk of APAP-induced liver injury [3]. To account for the 598 
fact that many overdose patients have an increased underlying susceptibility to APAP-induced 599 
liver injury, we optimise our model against both fed and fasted mouse data. Factors that result 600 
in an APAP overdose patient being deemed “high-risk” such as alcohol consumption or 601 
malnutrition are known to deplete intracellular GSH stores, which subsequently increases their 602 
risk of potential toxicity [45]. Fasted animals have also been shown to have depleted GSH 603 
stores [46] and hence they are considered to be representative of high-risk individuals in our 604 
framework. When training the biomarker models against multiple datasets and comparing to 605 
the original model [20], which is calibrated against only 530 mg/kg APAP dose time-course 606 
data, there are noticeable adjustments in the parameter values, particularly for the GSH 607 
model. Many of these changes are intuitive and may be representative of changes in 608 
mechanisms due to fasting. Additionally, changes may be attributable to the fact that the model 609 
can now better account for a larger variety of dosing scenarios. The significant changes in 610 
parameter values highlight the importance of optimising against a range of both therapeutic 611 
and toxic datasets and both healthy and unhealthy populations.  612 
The model we propose in this paper is more biologically relevant than our previous model [20]. 613 
Originally, we assume that full and fragmented K18 have similar mechanisms and act as 614 
independent biomarkers. However, full and fragmented K18 are known to be effectively 615 
necrotic/apoptotic versions of the same biomarker [47]. Incorporating this into our model 616 
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framework we confirm that necrosis is the pre-dominant form of cell death in mice APAP 617 
overdose cases [48]. An identifiability analysis on the new model structure identifies an 618 
increased confidence in parameter estimates for the GSH, HMGB1, full and fragmented K18 619 
components of the model structure. There are, however, some unidentifiabilities remaining, 620 
particularly within the HMGB1 and fragmented K18 components of the model, indicating that 621 
additional data and model development is still required in order to have full confidence in the 622 
uniqueness of chosen mechanistic parameter values. 623 
We provide a proof of-concept framework which can be used to make toxicity predictions for 624 
either a healthy, high-risk or mixed population. In practice, once a dose/time is determined 625 
using the multiple linear regression statistical model, probability of liver injury can be estimated 626 
based on the HMGB1-dependent logistic regression model, driven by PK simulations with the 627 
previously identified dose/time values. The range of doses for which the high-risk population 628 
is likely to suffer liver injury (based on predictions made within this in-silico framework) is 629 
extensive. Prediction accuracy of time since APAP administration and initial APAP dose is 630 
similar for the healthy and mixed populations, with a 3-4 h error for time since administration 631 
and a 65-75 mg/kg error for initial dose. The initial dose is much harder to predict in the high-632 
risk population (184.1 mg/kg error). This result is unsurprising since a much larger range of 633 
doses will have a toxic effect if the liver is already impaired. Both Figure 8 and Table 4 show 634 
that in a high-risk population, any dose above approximately 60 mg/kg is highly likely to induce 635 
liver injury and therefore determining the exact dose in this scenario is difficult. Time since 636 
administration, however, could be predicted more accurately than in a healthy/mixed 637 
population (2.118 h error). It has already been found that amending treatment thresholds  to 638 
account for high-risk individuals can better protect those with greater liver injury susceptibility 639 
[3].  Table 4 shows that liver injury in a healthy individual is predicted to occur within 2-18 640 
hours following an APAP dose. For a high-risk individual however, this likelihood is predicted 641 
to continue for the whole time-course investigated (24 hours). Results from this study further 642 
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endorse the idea that there are likely very different outcomes with respect to liver injury 643 
potential for healthy and high-risk individuals. More-informed decisions can therefore be made 644 
regarding optimal treatment if clinicians can identify those who are more susceptible to 645 
overdose. This would significantly improve patient outcomes while reducing the cost and 646 
burden of unnecessary antidote treatment.  647 
The model was recalibrated to improve confidence in our approach and ensure that predictions 648 
are more clinically applicable prior to developing a clinical extension of the framework. The 649 
model has been calibrated against mouse data due to the quantity and quality of the toxicity 650 
data available, necessary for the rigorous development of a mathematical framework. Whilst 651 
metabolic similarities do exist between rodent and human (for example CYP2E1 expression), 652 
expression levels of enzymes such as CYP1A2 are known to vary across species [49], 653 
meaning direct translation of rodent-based models to the human case is rarely feasible and 654 
additional work may be required. Animal models account for the complex, physiological 655 
interplay within organisms, and therefore are often investigated during pharmacological 656 
research prior to application in humans. Although clinical APAP data is available, it is often 657 
sparse, erroneous and inherently highly variable. A Population-Pharmacokinetics (Pop-PK) 658 
approach could potentially provide insight into the stochasticity of the errors involved, but 659 
initially we have focused on the mouse framework as a convenient testing and development 660 
toolkit to determine efficacy in a well-controlled environment. The promising results of this 661 
study now provide confidence in the feasibility of translating our approaches to the human 662 
clinical case. Identifiability analysis has provided insight into areas within our model structure 663 
that remain uncertain, and therefore require additional consideration and improvement in order 664 
to enhance confidence in translated predictions. Regarding translation, all biomarkers used in 665 
the study can be measured in both animals and humans via the same methodologies. 666 
Inevitably, there are apparent differences between humans and mice such as the expression 667 
of metabolising enzymes, the mass APAP dose required to induce toxicity and the kinetics of 668 
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the biomarker profiles [44, 45]. However, the essential mechanistic processes of APAP 669 
metabolism, toxicity and action of the antidote are directly comparable. Our model accounts 670 
for a dose range 0-1000 mg/kg in mouse and this can be amended as a parameter within our 671 
model structure to be applicable to the clinical situation. In terms of the biomarkers used, they 672 
have now been measured in a time-dependent manner in multiple human studies [33, 41]. In 673 
its current form, our framework accounts for varied dose ranges and provides promise for 674 
clinical use in determining initial dose, time since ingestion and estimated probability of liver 675 
injury for both healthy and high-risk individuals. Further model development, integration of 676 
additional experimental data and translation to the clinical environment is now required to 677 
significantly advance this research to provide a state-of-the-art alternative to the methods 678 
currently used and considerably improve individualised treatment of APAP overdose. 679 
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